Postdoctoral Scientist Dr Joseph Newman Group Viral Glycoproteins Dr Joseph Newman Group Viral Glycoproteins Publications Wing, PAC, Schmidt, NM, Peters, R, Erdmann, M, Brown, R, Wang, H, Swadling, L; COVIDsortium Investigators; Newman, J, Thakur, N, Shionoya, K, Morgan, SB, Hinks, TS, Watashi, K, Bailey, D, Hansen, SB, Davidson, AD, Maini, MK, McKeating, JA (2023) An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity Journal PLOS Pathogens Read abstract Foster WS, Newman J, Thakur N, Spencer AJ, Davies S, Woods D, Godfrey L, Ross SH, Sharpe HJ, Richard AC, Bailey D, Lambe T, Linterman MA (2023) ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice Journal Immunology & Cell biology Read abstract Foster, WS, Lee, JL, Thakur, N, Newman, J, Spencer, AJ, Davies, S, Woods, D, Godfrey, L, Hay, IM, Innocentin, S, Yam-Puc, JC, Horner, EC, Sharpe, HJ, Thaventhiran, JE, Bailey, D, Lambe, T and Linterman, MA (2022) T follicular helper cells and the germinal centre are required for memory B cell formation and humoral immunity after ChAdOx1 nCoV-19 vaccination Journal Cell Reports Medicine Read abstract Kelly J T, Swanson J, Newman J, Groppelli E, Stonehouse N J, Tuthill T J (2022) Membrane interactions and uncoating of Aichi virus: a picornavirus that lacks a VP4 Journal Journal of Virology Read abstract van Doremalen N, Schulz J E, Adney D R, Saturday T A, Fischer R J, Yinda C K, Thakur N, Newman J, Ulaszewska M, Belij-Rammerstorfer S, Saturday G, Spencer A J, Bailey D, Russell C A, Gilbert S C, Lambe T, Munster V J (2022) ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants Journal Nature Communications Read abstract Pagination Previous page Prev Page 1 Page 2 Page 3 Page 4 Next page Next Articles 11 April 2022 Pirbright scientists investigate pig coronavirus infection to understand COVID-19 in humans Researchers at Pirbright have developed a pig respiratory coronavirus (PRCV) model which will help to understand how coronaviruses cause disease and how the immune system responds to them. Human coronaviruses such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS… Read more 07 April 2022 SARS-CoV-2 variants can infect a wider range of animal cells according to new research led by Pirbright SARS-CoV-2, the virus that causes COVID-19, can potentially infect a wider number of animal species including rodents and ferrets, reveal Pirbright scientists. The study found that SARS-CoV-2 variants Alpha, Beta and Delta can infect more species compared to the ancestral virus strain, this is due… Read more 22 January 2021 Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine Studies carried out by The Pirbright Institute and the University of Oxford have shown that Oxford’s new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this… Read more 23 June 2020 Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs The Pirbright Institute, working in collaboration with the University of Oxford, have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs. The emergence and subsequent spread of SARS-CoV-2 has caused a global… Read more 26 September 2018 Engineering ‘Fab’ new ways of reducing animal use in foot-and-mouth disease diagnostics A novel foot-and-mouth disease (FMD) diagnostic reagent has been developed by scientists at The Pirbright Institute. This has the potential to be used in FMD diagnostic tests, and will be significantly quicker to produce when compared to existing test reagents due to a simplified production… Read more 21 June 2018 Breakthrough could make the common cold not so common Researchers at The Pirbright Institute have helped in the development of a new molecule to treat a range of viruses including the common cold. In addition to the days of work lost due to illness, the common cold can cause complications in respiratory illnesses such as asthma and cystic fibrosis. The… Read more 12 December 2017 Protein shown vital for foot-and-mouth disease virus replication Researchers at The Pirbright Institute have shown that when drugs are used to inhibit the cellular protein, hsp90, foot-and-mouth disease virus (FMDV) production is reduced. Hsp90 is a protein used by cells to fold other proteins correctly and it was shown to be required by FMDV to form the outer… Read more Contact Title Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Submit message
Wing, PAC, Schmidt, NM, Peters, R, Erdmann, M, Brown, R, Wang, H, Swadling, L; COVIDsortium Investigators; Newman, J, Thakur, N, Shionoya, K, Morgan, SB, Hinks, TS, Watashi, K, Bailey, D, Hansen, SB, Davidson, AD, Maini, MK, McKeating, JA (2023) An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity Journal PLOS Pathogens Read abstract
Foster WS, Newman J, Thakur N, Spencer AJ, Davies S, Woods D, Godfrey L, Ross SH, Sharpe HJ, Richard AC, Bailey D, Lambe T, Linterman MA (2023) ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice Journal Immunology & Cell biology Read abstract
Foster, WS, Lee, JL, Thakur, N, Newman, J, Spencer, AJ, Davies, S, Woods, D, Godfrey, L, Hay, IM, Innocentin, S, Yam-Puc, JC, Horner, EC, Sharpe, HJ, Thaventhiran, JE, Bailey, D, Lambe, T and Linterman, MA (2022) T follicular helper cells and the germinal centre are required for memory B cell formation and humoral immunity after ChAdOx1 nCoV-19 vaccination Journal Cell Reports Medicine Read abstract
Kelly J T, Swanson J, Newman J, Groppelli E, Stonehouse N J, Tuthill T J (2022) Membrane interactions and uncoating of Aichi virus: a picornavirus that lacks a VP4 Journal Journal of Virology Read abstract
van Doremalen N, Schulz J E, Adney D R, Saturday T A, Fischer R J, Yinda C K, Thakur N, Newman J, Ulaszewska M, Belij-Rammerstorfer S, Saturday G, Spencer A J, Bailey D, Russell C A, Gilbert S C, Lambe T, Munster V J (2022) ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants Journal Nature Communications Read abstract
11 April 2022 Pirbright scientists investigate pig coronavirus infection to understand COVID-19 in humans Researchers at Pirbright have developed a pig respiratory coronavirus (PRCV) model which will help to understand how coronaviruses cause disease and how the immune system responds to them. Human coronaviruses such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS… Read more
07 April 2022 SARS-CoV-2 variants can infect a wider range of animal cells according to new research led by Pirbright SARS-CoV-2, the virus that causes COVID-19, can potentially infect a wider number of animal species including rodents and ferrets, reveal Pirbright scientists. The study found that SARS-CoV-2 variants Alpha, Beta and Delta can infect more species compared to the ancestral virus strain, this is due… Read more
22 January 2021 Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine Studies carried out by The Pirbright Institute and the University of Oxford have shown that Oxford’s new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this… Read more
23 June 2020 Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs The Pirbright Institute, working in collaboration with the University of Oxford, have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs. The emergence and subsequent spread of SARS-CoV-2 has caused a global… Read more
26 September 2018 Engineering ‘Fab’ new ways of reducing animal use in foot-and-mouth disease diagnostics A novel foot-and-mouth disease (FMD) diagnostic reagent has been developed by scientists at The Pirbright Institute. This has the potential to be used in FMD diagnostic tests, and will be significantly quicker to produce when compared to existing test reagents due to a simplified production… Read more
21 June 2018 Breakthrough could make the common cold not so common Researchers at The Pirbright Institute have helped in the development of a new molecule to treat a range of viruses including the common cold. In addition to the days of work lost due to illness, the common cold can cause complications in respiratory illnesses such as asthma and cystic fibrosis. The… Read more
12 December 2017 Protein shown vital for foot-and-mouth disease virus replication Researchers at The Pirbright Institute have shown that when drugs are used to inhibit the cellular protein, hsp90, foot-and-mouth disease virus (FMDV) production is reduced. Hsp90 is a protein used by cells to fold other proteins correctly and it was shown to be required by FMDV to form the outer… Read more
